Free Trial

Lyra Therapeutics (LYRA) Insider Trading & Ownership

Lyra Therapeutics logo
$0.21 0.00 (-0.19%)
(As of 11:57 AM ET)

Lyra Therapeutics (NASDAQ:LYRA) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
4.69%
Number Of
Insiders Buying
(Last 3 Years)
6
Amount Of
Insider Buying
(Last 3 Years)
$24.99 M
Number Of
Insiders Selling
(Last 3 Years)
0
Get LYRA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Lyra Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

LYRA Insider Buying and Selling by Quarter

Lyra Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2023Harlan WaksalInsiderBuy25,000$2.96$74,000.00  
5/31/2023Nbvm Gp, LlcMajor ShareholderBuy1,805,416$2.43$4,387,160.88  
5/31/2023Perceptive Advisors LlcDirectorBuy3,610,832$2.49$8,990,971.68  
6/10/2022C Ann MerrifieldDirectorBuy4,000$5.05$20,200.00  
5/16/2022C Ann MerrifieldDirectorBuy328$5.00$1,640.00  
5/13/2022C Ann MerrifieldDirectorBuy3,500$4.81$16,835.00  
4/12/2022Edward T AndersonDirectorBuy118,483$4.22$499,998.26  
4/12/2022Harlan WaksalInsiderBuy236,966$4.22$999,996.52  
4/12/2022Nbvm Gp, LlcMajor ShareholderBuy2,369,667$4.22$9,999,994.74  
(Data available from 1/1/2013 forward)

LYRA Insider Trading Activity - Frequently Asked Questions

The list of insiders at Lyra Therapeutics includes C Ann Merrifield, Edward T Anderson, Harlan Waksal, Nbvm Gp, Llc, and Perceptive Advisors Llc. Learn more on insiders at LYRA.

4.69% of Lyra Therapeutics stock is owned by insiders. Learn more on LYRA's insider holdings.

The following insiders have purchased LYRA shares in the last 24 months: Harlan Waksal ($74,000.00), Nbvm Gp, Llc ($4,387,160.88), and Perceptive Advisors Llc ($8,990,971.68).

Insiders have purchased a total of 5,441,248 LYRA shares in the last 24 months for a total of $13,452,132.56 bought.

Lyra Therapeutics Key Executives

  • Dr. Harlan W. Waksal M.D. (Age 71)
    Executive Chairman
    Compensation: $210.06k
  • Dr. Maria Palasis Ph.D. (Age 59)
    CEO, President & Director
    Compensation: $942.7k
  • Dr. John E. Bishop Ph.D. (Age 62)
    Chief Technology Officer
    Compensation: $662.9k
  • Dr. Carmichael S. Roberts Jr. (Age 55)
    Ph.D., Co-Founder
  • Mr. Jason Cavalier (Age 51)
    CFO, Treasurer & Secretary
    Compensation: $464.11k
  • Mr. Ray Knox
    Vice President of Operations
  • Ms. Ellen Cavaleri
    Senior Vice President of Investor Relations & Communications
  • Mr. Ronan P. O'Brien J.D. (Age 51)
    Chief Legal Officer
  • Ms. Corinne Noyes (Age 56)
    Senior Vice President of Commercial Strategy & Market Development
    Compensation: $426.73k
  • Ms. Vineeta Belanger Ph.D.
    Senior Vice President of Clinical Affairs


This page (NASDAQ:LYRA) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners